Evidence map›Paper›PMID 36864326›Full record

ArticleAnnals of surgical oncology2023

Plasma Exosome Gene Signature Differentiates Colon Cancer from Healthy Controls.

Paul A Vallejos, Amber Gonda, Jingjing Yu, Brittany G Sullivan, Arsha Ostowari, Mei Li Kwong, Audrey Choi, Matthew J Selleck, Janviere Kabagwira, Ryan N Fuller and 6 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Paul A Vallejos *Department of Basic Science, Division of Biochemistry, Loma Linda University School of Medicine, Loma Linda, CA, USA.
Amber Gonda *Department of Surgery, Division of Surgical Oncology, University of California, Irvine Medical Center, Orange, CA, USA.
Jingjing YuDepartment of Surgery, Division of Surgical Oncology, University of California, Irvine Medical Center, Orange, CA, USA.
Brittany G SullivanDepartment of Surgery, Division of Surgical Oncology, University of California, Irvine Medical Center, Orange, CA, USA.
Arsha OstowariDepartment of Surgery, Division of Surgical Oncology, University of California, Irvine Medical Center, Orange, CA, USA.
Mei Li KwongDivision of Surgical Oncology, Loma Linda University Health, Loma Linda, CA, USA.
Audrey ChoiDivision of Surgical Oncology, Loma Linda University Health, Loma Linda, CA, USA.
Matthew J SelleckDivision of Surgical Oncology, Loma Linda University Health, Loma Linda, CA, USA.
Janviere KabagwiraDepartment of Basic Science, Division of Biochemistry, Loma Linda University School of Medicine, Loma Linda, CA, USA.
Ryan N FullerDepartment of Basic Science, Division of Biochemistry, Loma Linda University School of Medicine, Loma Linda, CA, USA.
Daniel J GirondaDepartment of Cancer Biology, Wake Forest Health, Winston-Salem, NC, USA.
Edward A LevineDepartment of Surgery, Division of Surgical Oncology, Wake Forest Health, Winston-Salem, NC, USA.
Christopher C W HughesDepartment of Molecular Biology and Biochemistry, University of California, Irvine, Irvine, CA, USA.
Nathan R WallDepartment of Basic Science, Division of Biochemistry, Loma Linda University School of Medicine, Loma Linda, CA, USA.
Lance D MillerDepartment of Cancer Biology, Wake Forest Health, Winston-Salem, NC, USA.
Maheswari SenthilDepartment of Molecular Biology and Biochemistry, University of California, Irvine, Irvine, CA, USA. maheswas@hs.uci.edu.ORCID http://orcid.org/0000-0002-0339-8558
Loma Linda University · USUniversity of California, Irvine Medical Center · USWake Forest University · USUniversity of California, Irvine · US

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
Loma Linda University Grants to promote CollaborativeLoma Linda University TranslationalNCI NIH HHS P30 CA062203
6 · The paper itself

Abstract

backgroundLiquid biopsies have become an integral part of cancer management as minimally invasive options to detect molecular and genetic changes. However, current options show poor sensitivity in peritoneal carcinomatosis (PC). Novel exosome-based liquid biopsies may provide critical information on these challenging tumors. In this initial feasibility analysis, we identified an exosome gene signature of 445 genes (ExoSig445) from colon cancer patients, including those with PC, that is distinct from healthy controls.

methodsPlasma exosomes from 42 patients with metastatic and non-metastatic colon cancer and 10 healthy controls were isolated and verified. RNAseq analysis of exosomal RNA was performed and differentially expressed genes (DEGs) were identified by the DESeq2 algorithm. The ability of RNA transcripts to discriminate control and cancer cases was assessed by principal component analysis (PCA) and Bayesian compound covariate predictor classification. An exosomal gene signature was compared with tumor expression profiles of The Cancer Genome Atlas.

resultsUnsupervised PCA using exosomal genes with greatest expression variance showed stark separation between controls and patient samples. Using separate training and test sets, gene classifiers were constructed capable of discriminating control and patient samples with 100% accuracy. Using a stringent statistical threshold, 445 DEGs fully delineated control from cancer samples. Furthermore, 58 of these exosomal DEGs were found to be overexpressed in colon tumors.

conclusionsPlasma exosomal RNAs can robustly discriminate colon cancer patients, including patients with PC, from healthy controls. ExoSig445 can potentially be developed as a highly sensitive liquid biopsy test in colon cancer.

Indexed as

Colonic NeoplasmsExosomesBayes TheoremBiomarkers, TumorHumansRNABiomarkers, TumorRNA

Identifiers

PMID36864326
PMCPMC10175396
OpenAlexW4322764044

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.